In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter

FASEB Journal

Volumn 14, Issue 15, 2000, Pages 2401-2413

  Efange, S M N ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Choline acetyltransferase; Positron emission tomography; Radiotracer; Single photon emission computed tomography

Indexed keywords

4 AMINOBENZOVESAMICOL; CARBON 11; CHOLINE ACETYLTRANSFERASE; DIHYDROTETRABENAZINE; IODINE 125; IODOVINYLDIHYDROTETRABENAZINE; MEMBRANE PROTEIN; METHOXYTETRABENAZINE; RADIOLIGAND; TETRABENAZINE; TRACER; TRITIUM; UNCLASSIFIED DRUG; VESAMICOL; VESAMICOL DERIVATIVE; VESICULAR ACETYLCHOLINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER; VINYL DERIVATIVE;

CHOLINERGIC NERVE CELL; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG PROTEIN BINDING; HUMAN; IMAGING; IN VIVO STUDY; LIGAND BINDING; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

TRITIUM;

EID: 0033668691     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.00-0204rev     Document Type: Review

References (83)

1. The status of PET radiochemistry for drug development and evaluation
2. Positron emission tomography: Background, possibilities and perspectives in neuroscience
3. The neuromuscular blocking action of 2-(4-phenylpiperidino)cyclohexanol (AH 5183)
4. Studies on the blocking action of 2-(4-phenylpiperidino)cyclohexanol (AH5183)
5. 3H]-piperidino)cyclohexanol
6. Quantitative autoradiography of brain binding sites for the vesicular acetylcholine transport blocker 2-(4-phenylpiperidino)cyclohexanol (AH5183)
7. 3H]Vesamicol binding in brain: Autoradiographic distribution, pharmacology, and effects of cholinergic lesions
8. Structure and organization of the Drosophila cholinergic locus
9. Molecular characterization of the mouse vesicular acetylcholine transporter gene
10. Cloning and expression of the vesamicol binding protein from the marine ray Torpedo. Homology with the putative vesicular acetylcholine transporter UNC-17 from Caenorhabditis elegans
11. Functional identification of a vesicular acetylcholine transporter and its expression from a 'cholinergic' gene locus
12. Molecular biology of the vesicular ACh transporter
13. Molecular cloning of a putative vesicular transporter for acetylcholine
14. A unique gene organization for two cholinergic markers, choline acetyltransferase and a putative vesicular transporter of acetylcholine
15. Distribution of the vesicular acetylcholine transporter (VAChT) in the central and peripheral nervous systems of the rat
16. Human and monkey cholinergic neurons visualized in paraffin-embedded tissues by immunoreactivity for VAChT, the vesicular acetylcholine transporter
17. Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles
18. Localization of two cholinergic markers, choline acetyltransferase and vesicular acetylcholine transporter in the central nervous system of the rat: In situ hybridization histochemistry and immunohistochemistry
19. Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles
20. 3H]vesamicol binding in temporal cortex of patients with Alzheimer's disease. Parkinson's disease and rats with basal forebrain lesions
21. 3H]Vesamicol binding in human brain cholinergic deficiency disorders
22. Interactions between the effects of basal forebrain lesions and chronic treatment with MDL 26,479 on learning and markers of cholinergic transmission
23. Vesamicol analogues as sigma ligands: Molecular determinants of selectivity at the vesamicol receptor
24. Choline acetyltransferase activity and vesamicol binding in Rett syndrome and in rats with nucleus basalis lesions
25. 125I]MIBT in primate brain
26. 2 receptor blockade in the 6-hydroxydopamine (6-OHDA)-lesioned rat: Possible implications for Parkinson's disease
27. Age-related diminution of dopamine antagonist-stimulated vesamicol receptor binding
28. Vesicular acetylcholine transporter (VAChT) density and Alzheimer's disease
29. 125I]iodobenzovesamicol binding reflects cortical cholinergic deficiency induced by specific immuno lesion of rat basal forebrain cholinergic system
30. 123I]MIBT
31. 18F]4-fluorobenzyltrozamicol. In vitro binding studies and positron emission tomography studies in nonhuman primates
32. Individual differences in cholinergic activity of aged rhesus monkeys revealed by PET
33. In vivo imaging of the spinal cord cholinergic system with positron emission tomography
34. PET imaging of spinal mechanisms of analgesia
35. Striatal D2/acetylcholine interactions: PET studies of the vesamicol receptor
36. PET studies of central cholinergic nerve terminals in animals and man
37. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM
38. In vivo mapping of cholinergic terminals in normal aging. Alzheimer's disease and Parkinson's disease
39. Regulation of the activity of striatal cholinergic neurons by dopamine
40. D1 and D2 dopamine receptors and the regulation of striatal acetylcholine release in vivo
41. Correlation of cholinergic abnormalities with senile plaques and mental scores in senile dementia
42. Correlation of cortical cholinergic and GABA deficits with quantitative neuropathological findings in senile dementia
43. Lewy body dementia - Clinical, pathological and neurochemical interconnections
44. Brain acetylcholinesterase activity is markedly reduced in dominantly-inherited olivopontecerebellar atrophy
45. Loss of cholinergic synapses on the spinal motor neurons of amyotrophic lateral sclerosis
46. Coordinate expression of vesicular acetylcholine transporter and choline acetyltransferase in sympathetic superior cervical neurones
47. Coregulation of two embedded gene products, choline acetyltransferase and the vesicular acetylcholine transporter
48. Coordinated up-regulation of choline acetyltransferase and vesicular acetylcholine transporter gene expression by retinoic acid receptor α, cAMP, and leukemia inhibitory factor ciliary neurotrophic factor signaling pathways in a murine septal cell line
49. Changes of expression levels of choline acetyltransferase and vesicular acetylcholine transporter mRNAs after transection of the hypoglossal nerve in adult rats
50. Coordinate expression of the vesicular acetylcholine transporter and choline acetyltransferase following septohippocampal lesions
51. Reduction of vesicular acetylcholine transporter mRNA in the rat septum following lead exposure
52. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease
53. The vesamicol receptor (VR): Radioligand selectivity and the detection of central cholinergic hypofunction
54. Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer's disease: Implications for etiology and therapy
55. Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of Meynert in Alzheimer's disease
56. The cholinergic system in Alzheimer's disease
57. Differences in the developmental expression of the vesicular acetylcholine transporter and choline acetyltransferase in the rat brain
58. Kinetic and equilibrium characterization of vesamicol receptor-ligand complexes with picomolar dissociation constants
59. Differential expression of two vesicular monoamine transporters
60. In vivo radiotracers for vesicular neurotransmitter transporters
61. Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles
62. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters
63. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones
64. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: A post-mortem study using tritiated tetrabenazine
65. 125I-iodovinyltetrabenazine to CNS vesicular monoamine transporter sites
66. 11C]tetrabenazine as an in vivo radioligand for the vesicular monoamine transporter
67. 11C]tetrabenazine
68. 3H]Methoxytetrabenazine: A high specific activity ligand for estimating monoaminergic neuronal integrity
69. 11C]MTBZ) in tottering mice
70. In vivo imaging of the brain vesicular monoamine transporter
71. 3H]dihydrotetrabenazine to the vesicular monoamine transporter of rat brain: Bolus vs equilibrium studies
72. 11C]dihydrotetrabenazine (DTBZ) and positron emission tomography
73. 11C]dihydrotetrabenazine by dynamic PET: Measurement of vesicular monoamine transporter
74. 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects
75. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease
76. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging
77. 11C]dihydrotetrabenazine and positron emission tomography
78. Decreased striatal monaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography
79. Decreased striatal monoaminergic terminals in multiple system atrophy detected with positron emission tomography
80. Striatal dopaminergic abnormalities in human cocaine users
81. Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic nerve terminals in human cocaine overdose victims
82. The vesicular monoamine transporter, in contrast to the dopamine transporter is not altered by chronic cocaine self-administration in the rat
83. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome